Strength & Growth Peptides: Growth Hormone Secretagogue Research
Growth hormone secretagogues (GHS) are a class of peptides studied for their interactions with the hypothalamic-pituitary growth hormone axis. These compounds have been investigated in preclinical models for their ability to modulate growth hormone release through receptor-mediated signaling, primarily via the ghrelin receptor (GHSR) and the growth hormone-releasing hormone receptor (GHRH-R). Published research has examined their selectivity profiles, pulsatile release patterns, and downstream effects in animal models.
Compounds in This Category
CJC-1295
A synthetic GHRH analog with a modified structure designed to extend half-life in research models. Studied for effects on GH pulsatility.
Ipamorelin
A pentapeptide GHS studied for selective GH release via the ghrelin receptor without significant effects on cortisol or prolactin in rodent models.
IGF-1
Insulin-like Growth Factor 1, a peptide studied for its role in the GH/IGF-1 signaling axis and its interactions with cellular proliferation pathways.
Tesamorelin
A synthetic GHRH analog investigated in preclinical and clinical research for its effects on growth hormone secretion and body composition parameters.
Research Context
The GH secretagogue class includes two distinct receptor targets: the GHRH receptor and the ghrelin receptor (GHSR). CJC-1295 and Tesamorelin act through the GHRH receptor pathway, while Ipamorelin signals through GHSR. This distinction is significant in research design, as the two receptor systems produce different GH release kinetics and downstream signaling profiles.
Ipamorelin has attracted particular research interest due to its observed selectivity. A 2009 study published in the European Journal of Endocrinology examined Ipamorelin's effects in rat models and observed growth hormone release without significant concurrent increases in cortisol, prolactin, or ACTH — a selectivity profile that distinguishes it from earlier-generation GHS compounds like GHRP-6 (PMID: 19022896).
CJC-1295 research has focused on the peptide's extended pharmacokinetic profile. Its modified structure (including a Drug Affinity Complex or DAC variant) was designed to resist enzymatic degradation, resulting in an extended half-life compared to native GHRH. Published studies have examined the resulting sustained GH elevation patterns in laboratory settings.
The combination of CJC-1295 and Ipamorelin has been studied based on the rationale that simultaneous activation of both the GHRH receptor and the ghrelin receptor may produce amplified GH pulsatility compared to either compound alone. This dual-pathway approach is a common research paradigm in GH secretagogue studies.
Related Categories
Explore the Science
Read our comprehensive overview of peptide research, synthesis, and quality standards.
What Are Peptides? →The information presented on this page is for educational and informational purposes only and is not intended as medical advice. All products referenced are sold as research chemicals for laboratory use only. They are not intended for human consumption, and should not be used to diagnose, treat, cure, or prevent any disease. All references to published research are provided for informational context. Consult qualified professionals for guidance related to any health condition.